By David Wallace – September 1, 2026 The U.S. Food and Drug Administration approved Mimrylo™ (mim-rahy-loh), the brand name for rusfertide, on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera (PV). Erythrocytosis means the body is making too many red blood cells. Mimrylo is the first FDA-approved hepcidin mimetic for […]
Rusfertide Cuts Phlebotomies by 77% in Polycythemia Vera
by David Wallace Key Points Rusfertide achieved clinical response in 77% of patients compared to 33% with placebo in the Phase 3 VERIFY trial The drug significantly reduced the number of blood draws needed each year and decreased PV-related symptoms Rusfertide maintained hematocrit levels below 45% and reduced or eliminated the need for phlebotomy Safety […]
